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Objective 
To compare the effectiveness and safety of aprotinin use in adult patients undergoing thoracic aortic 
surgery. 
 
Design 
Single center retrospective study. 
 
Setting 
All cases performed at a single university hospital. 
 
Participants 
Between January 2004 and December 2014, 846 adult patients underwent thoracic aortic surgery. Due 
to missing or duplicated data on primary outcomes, 314 patients were excluded. The final sample of 
532 patients had operations on the thoracic aorta. 
 
Intervention 
The patients were divided in two groups: a total of 107 patients (20.1%) received aprotinin during the 
operation representing the study group, while the remaining 425 patients (79.9%) underwent surgery 
without the use of aprotinin.   
 
Measurements and Main Results 
To adjust for patient selection and preoperative characteristics, a propensity score-matched analysis 
was conducted. Mean total blood loss at 12 hours after surgery was similar between the two groups. 
The blood product transfusion rates did not differ in the two groups apart for the rate of fresh frozen 
plasma transfusion, being significantly higher in the aprotinin group. Re-exploration for bleeding and 
the incidence of a major post-operative bleeding event were similar between the groups. In-hospital 
mortality, renal failure and cerebrovascular accidents did not show any statistically significant 
difference. Aprotinin did not represent a risk factor for mortality over the long term outcome (HR 
1.14,  95%CI 0.62-2.08, p=0.66).  
 
Conclusions 
The use of aprotinin demonstrated a limited effect in reducing post-operative bleeding and prevention 
of major bleeding events. Aprotinin did not adversely affect early outcomes and long term survival. 
 
Introduction 
Patients undergoing cardiac surgery are at increased risk for excessive perioperative blood 
loss requiring transfusion of blood products, mainly due to the effects of preoperative 
medications, cardiopulmonary bypass (CPB) and hypothermia which can cause 
thrombocytopenia and platelet dysfunction, dilution and consumption of coagulation factors, 
hyper fibrinolysis and residual heparin effect. Intraoperative and postoperative bleeding 
remains a major complication of aortic surgery, having a significant impact on the clinical 
outcomes [1]. A strong relationship between bleeding after cardiac surgery and subsequent 
mortality has been already described, although it is not completely clear whether this is 
attributable to blood loss or transfusion-related side effects. Recently, a large single-center 
retrospective analysis in all types of cardiac surgery, has found major bleeding event was an 
independent predictor of operative mortality [2].  
Three anti-fibrinolytic agents (aprotinin, tranexamic acid and aminocaproic acid) are 
commonly used to minimize bleeding and reduce the need for blood products after cardiac 
surgery [3]. Aprotinin is a nonspecific serine protease inhibitor associated with reduced 
inflammatory response and organ-protective effects [4].  The mechanism for these beneficial 
effects includes inhibition of kallikrein, preservation of platelet membranes, inhibition of 
neutrophil activation and decrease in fibrinolysis [5-7]. Several randomized controlled trials 
have shown that aprotinin decreases perioperative bleeding and the need for allogenic blood 
transfusions [8,9]. However, concerns about the safety of aprotinin have been raised based on 
findings from observational studies suggesting that aprotinin was associated with increased 
renal dysfunction, cerebrovascular accidents and mortality [10-12].  
Limited data are available about the effect of aprotinin in thoracic aortic surgery. Here we 
report a single centre retrospective analysis comparing the early and mid-term clinical 
outcomes in patients undergoing adult thoracic aortic surgery with or without the use of 
aprotinin. 
Materials and methods 
Study population 
This is a single centre retrospective observational study on prospectively collected data 
obtained from our institutional cardiac surgery dataset with some customized variables (i.e. 
postoperative bleeding, use of blood products). Between January 2004 and December 2014, 
846 adult patients underwent thoracic aortic surgery at Bristol Heart Institute. Data on our 
primary outcomes were not available for the entire population: for this reason and/or 
duplicated record we have excluded 314 patients (figure 1). The final sample of 532 patients 
had operations on the thoracic aorta and included patients requiring circulatory arrest and 
surgery for acute aortic syndrome. The patients were divided in two groups: a total of 107 
patients (20.1%) received aprotinin during the operation representing the study group, while 
the remaining 425 patients (79.9%) underwent surgery without the use of aprotinin.   
  
End-point and definitions  
Our primary end points were post-operative bleeding, reoperation for bleeding and/or 
tamponade and transfusion of blood products (packed red blood cells, platelets, fresh frozen 
plasma and cryoprecipitate). A composite outcome of major bleeding was defined as 12 hours 
post-operative bleeding exceeding the 90th percentile of the entire distribution and/or the 
need for reoperation for post-operative bleeding. This parameter was found to be an 
independent risk factor for postoperative mortality in cardiac surgery [2].  
In-hospital mortality was defined as death due to all causes within 30 days from the day of 
surgery. 
Secondary outcomes included acute kidney injury (AKI) defined as per RIFLE criteria (Risk, 
Injury, Failure, Loss of function, and End-stage renal disease) using maximal change in 
serum creatinine (sCr) [13], evidence of post-operative stroke (defined clinical and 
radiological evidence of a new post-operative cerebrovascular event (CVA)) and long term 
survival.  
 
Surgical and intensive care management 
Aprotinin was administered as a 280 mg (2x106 kIU) loading dose, followed by a 
maintenance infusion of 70 mg/h and priming of the cardiopulmonary bypass pump with 280 
mg.  
Anticoagulation during CPB was achieved with unfractionated heparin according to standard 
protocols: the initial dose was 300 IU/kg adjusted with further administration to achieve and 
maintain an activated clotting time (ACT) higher than 480 seconds. Heparin reversal was 
achieved with protamine sulphate (100 mg per 300 units of heparin) to normalize ACT after 
CPB. The indication for re-sternotomy for excessive bleeding was made on the basis of 
individual patient clinical status mainly depending on the amount of blood drainage from the 
thoracic drains, hemodynamic instability and/or signs of cardiac tamponade. The indication 
for blood product transfusion was not guided by a specific protocol, although the usual cut-
off for red blood cells transfusion was a haemoglobin value less than 8 g/dL.  
Following the withdraw of the aprotinin, all the patients not treated with aprotinin received 
tranexamic acid as per our institutional protocol: after induction of anesthesia and prior to 
skin incision a pre-surgical loading dose of 15 mg/kg followed by infusion of 4.5 mg/kg/hour 
for the duration of surgery; 0.6 mg/kg of this infusion dose may be added in the priming 
volume of the heart-lung machine. 
 
Statistical analysis  
Data are presented as mean ± one standard deviation for continuous variables or as 
percentages of the total for dichotomous variables. Continuous variables were tested for 
normality using the Kolmogorov-Smirnov test and then compared between groups with 
unpaired Student’s t test if normally distributed or Mann-Whitney U test if not normally 
distributed. In the case of dichotomous or categorical variables Pearson chi-squared or 
Fisher’s exact test were used as appropriate. Overall long-term survival was estimated by 
Kaplan–Meier analysis. Comparison between unadjusted overall group survivals was 
assessed by the log–rank test. To further adjust for patient selection and preoperative 
characteristics, a propensity score-matched analysis and multivariable logistic regression 
analysis was conducted. The group of patients who did not receive aprotinin was 1:1 matched 
to the group of patients who did receive it using those preoperative variables which had a p 
value<0.1 in the unmatched analysis. This resulted in 2 matched groups with 107 patients 
each group. After matching, the 2 groups were compared using the paired t test or Wilcoxon 
test for continuous variables and the McNemar or Fisher exact test for categorical variables. 
Multivariable logistic regression analysis for independent predictor of major bleeding events 
was carried out. A stepwise approach was used and confirmed by backward/forward methods 
with Akaike information selection criteria. The significance within the models was evaluated 
with the Wald test, whereas the strength of the association of variables with postoperative 
major bleeding was estimated by calculating the odds ratio (OR) and 95% confidence 
intervals (CI). Long term survival has been described with the Kaplan-Meier method and the 
comparison between groups has been made using the log-rank test. Independent predictors of 
long term survival were evaluated with a Cox proportional hazard model.  
All tests were two-sided with the alpha level set at 0.05 for statistical significance. The 
statistical analysis was computed using R version 3.0.2 for Windows (R Foundation for 
Statistical Computing, Vienna, Austria).  
Results  
Unmatched analysis 
The overall in-hospital mortality was 5.45%. There was a higher not statistically significant 
mortality rate in the aprotinin compared to the non aprotinin group (7.5% vs 4.9 %, p=0.33). 
Preoperative and operative characteristics are shown in tables 1 and 2 (unmatched 
population). The two groups were similar in terms of demographic and main pre-operative 
characteristics, although aprotinin patients were more frequently operated in an emergency 
setting (31.7 % vs 18.8%, p <0.01) and had a higher preoperative creatinine level. The 
number of patients operated for type A aortic dissection was similar (23.3% vs 18.3%, 
p=0.27). The operative times were similar between the two groups (table 2): cardiopulmonary 
bypass time was 159.9 ± 64.8 minutes (median 149, IQR 75) in group A and 164.3 ± 72.5 
minutes (median 148, IQR 67) in group B (p = 0.88); aortic cross-clamp time was 96.3 ± 42.7 
minutes (median 95, IQR 57 min) vs 102.2 ± 47 minutes (median 95, IQR 57) respectively 
(p=0.35). There was a higher number of cases with deep hypothermic circulatory arrest 
(DHCA) in group A (43.9% vs 33.6%) although this difference had a borderline statistical 
significance (p=0.054); the DHCA time was significantly higher in group A (16.2 ± 19.6 vs 
10.3 ± 23.4 minutes respectively, p = 0.003). The overall mean post-operative bleeding in the 
first 12 hours after surgery was 520 ± 293 ml (median 450 ml, interquartile range 325 – 650 
ml); in the first 24 hours was 759 ± 499 ml (median 650 ml, interquartile range 450 - 925 ml). 
Fig. 2 shows a density plot for the post-operative chest drainage in the first 12 hours between 
the two groups: the mean  postoperative bleeding was marginally lower in the aprotinin group 
although this difference was not statistically significant (506.5 ± 300.8 ml in group A vs  
523.6 ± 292.2 ml in group B, p= 0.4). The occurrence of re-sternotomy for bleeding was also 
similar (6.5% vs 9.5%, p = 0.35). Major postoperative bleeding events involved 16 patients in 
the aprotinin group (14.9%) and 68 patients in the non-aprotinin group (16%, p = 0.88). Post-
operative major bleeding event was independently associated with a significantly higher 
postoperative in-hospital mortality (OR 3.05, 95% CI 1.36 - 6.8, p = 0.006). As expected, this 
subgroup of patients had also a higher rate of blood (70.2 vs 34.6%, p <0.01), platelets (47.6 
vs 7.4%, p<0.01) and fresh frozen plasma (36.9 vs 8.9%, p < 0.01) transfusions. Aprotinin 
did not appear to influence this outcome (OR 1.08, 95% CI 0.6-1.96, p=0.79). After 
multivariate logistic regression analysis, independent predictors for major bleeding were the 
need for DHCA (OR 1.8, 95% CI 1.13-3.08, p=0.01) and CPB time (OR 1.006, 95% CI 
1.001-1.010, p=0.04).  
Table 3 reports the total amount of transfusions. There was no difference in red blood cell 
(RBC), platelet (PLTs) and cryoprecipitate transfusions between groups. Interestingly a 
higher use of fresh frozen plasma (FFP) was found in the aprotinin group (24.3 % vs 10.6 %, 
p < 0.01).  
Postoperative AKI and CVA rates was not different between the two groups (33.6% vs 25.9, 
p=0.11 and 4.7% vs 2.5% , p = 0.44, respectively in aprotinin and non-aprotinin group).  
The Kaplan-Meier survival curves are shown in figure 3. The long term survival at 5 years 
was 79.3% in aprotinin patients and 78.2% in non aprotinin; at 10 years  was 58.5% vs 74.7 
% respectively (p=0.68). Table 4 shows the Cox’s proportional hazard model. Independent 
predictors for long term mortality were hypertension (HR 2.05, 95%CI 1.13-3.6, p=0.01), 
chronic obstructive pulmonary disease (HR 3.36, 95% CI 1.85-6.11, p<0.01), reduced left 
ventricular ejection fraction (HR 2.18, 95%CI 1.23-3.84, p<0.01), post-operative transfusions 
(HR 2.79 95% CI 1.8-3.4, p<0.01). Although long term survival at 10 years was lower, the 
Cox’s proportional hazard model indicated that the use of aprotinin did not significantly 
affect the outcome (HR 1.14, 95%CI 0.62-2.08, p=0.66). 
A further comparative analysis was conducted in the subgroup of patients who underwent 
DHCA (190 patients, 35.7% of the total cohort). We observed a tendency to less bleeding at 
12 hours in the aprotinin group (477.66 ± 312.09 ml vs 579.79 ± 337.09 ml) although not 
statistically significant (p = 0.06) and the incidence of re-sternotomy for bleeding was also 
similar (6.38% vs 8.39 %, respectively; p = 0.89). The volume of blood product transfusion 
was also similar. 
 
Matched analysis 
Distribution of baseline and operative characteristics for the matched analysis is shown in 
tables 1 and 2 (matched population). Those variables which were significantly different 
before matching were adjusted trough propensity score and were now comparable. The final 
number of patients was 107 for each group. 
The operative outcomes for the matched population are also shown in table 3. There was a 
higher but not statistically significant mortality rate in the aprotinin compared to the non 
aprotinin group even in the matched population (7.5% vs 6.5%, p=1). Twelve hours bleeding 
was similar in the two groups (median 450 ml, IQR 325 in the aprotinin group vs. median 
500 ml, IQR 362 in the non-aprotinin group, p = 0.15). Major postoperative bleeding events 
involved 16 patients in the aprotinin group (15%) and 21 patients in the non-aprotinin group 
(21%, p = 0.44). There was no difference in red blood cell (RBC), platelet (PLTs) and 
cryoprecipitate transfusions between groups. As already seen in the unmatched group, a 
higher use of fresh frozen plasma (FFP) was found in the aprotinin group (24.3 % vs 11.2%, 
p < 0.01). 
Re-sternotomy for bleeding was also similar (6.5% vs 8%, p = 0.15). Postoperative AKI and 
CVA rates was not different between the two matched groups (33.6% vs 29%, p = 0.11 and 
4.7% vs 5.6% , p = 0.44, respectively in aprotinin and non-aprotinin group).  
Discussion 
There were three main findings in our study. First, the use of aprotinin did not significantly 
reduce post-operative bleeding and blood product transfusion rate; secondly, we did not find 
aprotinin to confer more risk in terms of in-hospital morbidity and mortality; last, long term 
survival was not significantly different between groups.  
The use of aprotinin in cardiac surgery has been extensively debated; however, just a few of 
the available analysis have focused on a selected cohort of thoracic aortic surgery patients. 
Thoracic aortic surgery  with or without DHCA is associated with significant post-operative 
bleeding, even in the hands of experienced surgeons[14,15]: it may lead to severe bleeding 
due to surgical reasons such as poor quality atherosclerotic tissues, coagulopathy due to 
longer CPB times and hypothermia. Some authors have speculated that the most important 
factors to prevent blood loss in this type of surgery are secure suture lines and the experience 
of the surgical and anesthesiology team as early aggressive management of coagulopathy is 
critical[16]. Our study is a contemporary series reporting accurate measurements of post-
operative bleeding after thoracic aortic surgery. The lack of significant differences in 
bleeding and re-exploration rates between groups suggests that meticulous surgical technique 
and particular attention to haemostasis are crucial and may play a larger role than aprotinin 
for reduction of bleeding. Our analysis confirms the prominence of bleeding-related 
complications in aortic surgery with 15.1% of the patients bleeding more than 800 ml in the 
first 12 hours and a blood product transfusion rate of 45.3%. These results are in line with 
similar studies: in a retrospective analysis of thoracic aortic surgery in DHCA[14], Mora 
Mangano et al. showed no differences in terms of post-operative chest drainage between 
aprotinin and non-aprotinin patients, with a first 12 hours bleeding of 947 vs 761 ml 
respectively (p 0.33). Sedrakyan and colleagues [15], in contrast, showed that there is some 
evidence of reduction in 24-hour drainage in patient receiving aprotinin compared with a 
control group, although they considered bleeding at 24 hours that, in our opinion, is not the 
ideal timing to assess the postoperative bleeding in thoracic aortic surgery, generally 
associated with severe bleeding and re-exploration in a shorter period of time. In order to 
reduce the higher risk of bleeding and subsequent need for blood product transfusion, in the 
last years our practice is evolving towards moderate hypothermia (26-28°C) to avoid DHCA, 
with increasing use of axillary artery as site of arterial cannulation and antegrade cerebral 
perfusion for brain protection.  
In our study, the RBC transfusion rate was not significantly different between groups both in 
the unmatched and matched analyses. This result cannot be correlated to the use of aprotinin 
only as many other variables could have influenced RBC transfusion such as pre-operative 
anaemia, haemodilution, type of surgery and the local thresholds for transfusions. Therefore, 
RBC transfusion rates alone should not be used to judge the effectiveness of aprotinin in high 
bleeding risk cardiac surgery. The use of platelets and FFP would probably be more 
appropriately related to post-operative bleeding: interestingly we found a higher use of FFP 
in the aprotinin group (unmatched analysis 24.3 % vs 10.6 %, p < 0.01; matched analysis 
24.3% vs 11.2%, p<0.01), with no difference in the use of platelets (unmatched analysis 
13.1% vs 13.9%, p=0.95; matched analysis 13.1% vs 15%, p=0.83). In the last two decades 
the rule of prophylactic use of FFP transfusion as part of blood conservation strategies has 
changed. The most recent STS and SCA guidelines on blood conservation clinical practice in 
cardiac surgery [17] have revised the clinical indications for plasma use, limiting them 
mainly to serious bleeding or surgical procedures in the context of multiple or single 
coagulation factor deficiencies when safer fractionated products are not available. A systemic 
review of six clinical trials including a total of 363 patients undergoing cardiac procedures 
showed no improvement in blood conservation with prophylactic use of plasma [18]. Another 
review identified seven additional randomized trials of FFP used in cardiovascular 
procedures (including pediatric operations), and found no association between use of FFP and 
reduced surgical blood loss [19]. Despite several limitations, the results of FFP trials are 
consistent, and the available evidence suggests that the prophylactic use of plasma in routine 
cardiac surgeries is not associated with reduced blood loss or less transfusion requirement, 
and this practice is not recommended any more. Our results reflect a change in the FFP use in 
our institution across the years, with a reduction in their prophylactic transfusion from 2011, 
since the most recent guidelines were published.  
Furthermore, aprotinin interferes with all the current tests of the intrinsic coagulation system; 
our institutional policy for continued blood product transfusion in patients who continued to 
bleed after arriving in intensive care involved thromboelastography followed by APTT.  The 
results of these tests would have driven the blood product transfusion policy, thus creating an 
additional mechanism of bias that led to a higher FFP transfusion rate in the study group. 
Similar results on increased use of FFP was shown by Jakobsen [20], while higher incidence 
of blood product transfusion in aprotinin group was  reported by Mora Mangano’s study [14], 
where patient treated with aprotinin received more blood products intra-operatively. In a 
more recent study on thoracic aortic surgery [21], the authors reported a general trend toward 
less overall blood product transfusion in the aprotinin group. An older study, published in 
2000 investigated the impact of the aprotinin use on 23 patients undergoing thoracic aortic 
surgery with DHCA showing a significant reduction in the need for blood products in a 
subgroup of patients who received low-dose aprotinin [22]. De Santis and colleagues have 
shown an increased blood product need in adult cardiac surgery in the post BART era 
[23].Previous reports have correlated administration of aprotinin with post-operative 
cardiovascular complications and reduced survival rate [10,11,24,25]. In 2008 the result from 
Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART)[12] were 
published: this was a multicenter randomized controlled trial comparing efficacy and safety 
of anti- fibrinolytic agents. The trial was terminated earlier because of a higher rate of death 
in patients receiving aprotinin.  As immediate effect, the use of aprotinin was discontinued. 
More recent studies [23,26,27] have refuted this claim and re-validated its efficacy and safety 
resulting in reintroduction into clinical practice [28]. Since then, several series and expert 
reviews have been published with positive comments on the effects and safety of aprotinin 
[29-31].  
Thoracic aortic surgery patients represent a high risk population for postoperative 
complications like AKI and stroke [32,33]:  therefore this subgroup of patients represents an 
interesting population for analysis to further evaluate the impact of aprotinin on post-
operative complications. We did not find differences between the two groups with respect to 
short term outcomes. In-hospital mortality, postoperative AKI and stroke rate were 
comparable between the two groups. Midterm and long term survival after cardiac surgery is 
influenced by many factors such as the preoperative risk profile, the type of operation and the 
post-operative complications. In our study, the Kaplan-Meier survival curves for both groups 
showed a slightly worse survival at 10 years in the aprotinin group; however, the Cox’s 
proportional hazard model indicated that the use of aprotinin did not affect significantly the 
survival in the long term.  
Our study has several limitations: it is a retrospective analysis of a single center experience 
involving a relatively small cohort of patients, and due to missing values on main outcomes 
around 1/3 of the entire population has been excluded from the analysis. Although we 
analyzed a select cohort of patients, there is still a degree of heterogeneity: in fact, it involves 
higher risk procedures like type A dissection with DHCA and less risky procedure like 
elective ascending aorta replacements.  
In conclusion, in our thoracic aortic surgical practice, the use of aprotinin demonstrated a 
limited effect in reducing post-operative bleeding and prevention of major bleeding events. It 
did not have detrimental effects on  short–term clinical outcomes and did not compromise 
long-term survival. A new prospective randomized trial would be desirable to better 
understand the efficacy of aprotinin especially in the subgroup of patients who have a higher 
risk of post-operative bleeding.   
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Figure legends: 
Fig 1. Patients selection flowchart. 
Fig 2. Density plot for total chest drainage by aprotinin use in the first 12 post-operative 
hours. 
Fig 3. Kaplan-Meier Survival curves between the two groups. 
 
Table 1. Preoperative characteristics of the study cohort 
 
Unmatched population 
 
Matched population 
Characteristic 
Aprotinin  
(n=107) 
  
Non 
Aprotinin 
(n=425) 
  p Value 
 
Aprotinin 
(n=107) 
  
Non 
Aprotinin 
(n=107) 
  p Value 
      
      Age (years, median, IQR) 59(15)  60(23) 
 
0.93 
 
59(15) 
 
60(15) 
 
0.55 
Female gender 37(34.5)  144(33.8) 
 
0.9 
 
37(34.5) 
 
31 (39) 
 
0.42 
BMI (Kg/m2 - mean ± SD) 27.3±4.8  27.4±4.9 
 
0.85 
 
27.3±4.8 
 
27.7±5.3 
 
0.67 
Reduced LVEF 22(20.5)  67(15.7) 
 
0.24 
 
22(20.5) 
 
21 (19.6) 
 
1 
COPD/Asthma 11(10.2)  60(14.1) 
 
0.34 
 
11(10.2) 
 
19 (17.8) 
 
0.18 
Diabetes 1(0.9)  10(2.3) 
 
0.7 
 
1(0.9) 
 
4 (3.7) 
 
0.37 
Hypertension 68(63.5)  238(56) 
 
0.66 
 
68(63.5) 
 
61 (57) 
 
0.4 
Previous CVA 7(6.5)  21(4.9) 
 
0.47 
 
7(6.5) 
 
2 (1.9) 
 
0.17 
Smoking History     0.5 
 
 
   
0.59 
      Current 16(14.9)  49(11.5) 
 
 
 
16(14.9) 
 
17 (15.9) 
        Ex Smoker 43(40.1)  159(37.4) 
 
 
 
43(40.1) 
 
41 (38.3) 
  PVD 9(8.4)  51(12) 
 
0.43 
 
9(8.4) 
 
17 (15.9) 
 
0.21 
Creatinine (median, IQR) 95(33)  90(31) 
 
<0.01 
 
95(33) 
 
94.5 (30) 
 
0.1 
Euroscore (median, IQR) 9(3)  8(4) 
 
0.21 
 
9(3) 
 
9(4) 
 
0.44 
Sinus Rhytm 90(84.1)  383(90.1) 
 
0.08 
 
90(84.1) 
 
90 (84.1) 
 
1 
Nonelective surgery 51(47.6)  162(38.1) 
 
0.07 
 
51(47.6) 
 
46 (43.0) 
 
0.42 
Emergency surgery 34(31.7)  80(18.8) 
 
<0.01 
 
34(31.7) 
 
34 (31.8) 
 
1 
Previous Cardiac Surgery 23(21.4)  71(16.7) 
 
0.26 
 
23(21.4) 
 
17 (15.9) 
 
0.41 
Definitions: BMI: body mass index; LVEF: Left Ventricular Ejection Function, COPD: Chronic Obstructive Pulmonary Disease, 
CVA: cerebro-vascular accident, PVD: peripheral vascular disease,  IQR: interquartile range, SD: standard deviation. Kg: 
Kilograms, m2: square meters, min: minutes.    Data are expressed as number of events and percentages or otherwise expressed 
 
 
 
Table 2. Operative characteristics  
 
Unmatched population 
 
Matched population 
Characteristic 
Aprotini
n  
(n=107) 
  
Non 
Aprotini
n (n=425) 
  
p 
Value 
  
Aprotini
n (n=107) 
  
Non 
Aprotini
n (n=107) 
  
p 
Value 
Treated Aortic Segment: 
    
0.18 
     
0.25 
     Ascending Aorta/Arch 54(50.4) 
 
247(58.1) 
  
 
54(50.4) 
 
60(56.1) 
       Aortic Root 53(49.5) 
 
178(41.8) 
  
 
53(49.5) 
 
47(43.9) 
  Type A aortic dissection 25(23.3) 
 
78(18.3) 
 
0.27 
 
25(23.3) 
 
27 (25.2) 
 
0.85 
CPB time (min - median,IQR) 149(75) 
 
148(67) 
 
0.88 
 
149(75) 
 
170(73) 
 
0.51 
ACC time (min - median, 
IQR) 
95(57) 
 
101(51) 
 
0.35 
 
95(57) 
 
104(46) 
 
0.44 
Use of DHCA 47(43.9) 
 
143(33.6) 
 
0.54 
 
47(43.9) 
 
43 (40.2) 
 
0.63 
Definitions: CPB: cardio-pulmonary bypass, ACC: Aortic cross-clamp, DHCA: deep hypothermic circulatory arrest.  IQR: 
interquartile range, min: minutes. Data are expressed as number of events and percentages or otherwise expressed                 
 
 
 
  
Table 3. Operative outcomes between the two groups 
 
  
 
Unmatched population 
 
Matched population 
Characteristic 
Aprotini
n  
(n=107) 
  
Non 
Aprotini
n 
(n=425) 
  
p 
Value 
  
Aprotini
n 
(n=107) 
  
Non 
Aprotini
n 
(n=107) 
  
p 
Value 
In Hospital Mortality 8 (7.5) 
 
21(4.9) 
 
0.33 
 
8 (7.5) 
 
7 (6.5) 
 
1 
Major Bleeding 
16 
(15.0) 
 
68(16) 
 
0.88 
 
16 
(15.0) 
 
21 
(19.6) 
 
0.44 
            Transfusion 
           
      RBC transfusion 
39 
(36.4) 
 
175(41.
2) 
 
0.44 
 
39 
(36.4) 
 
51 
(47.7) 
 
0.09 
      PLT transfusion 
14 
(13.1) 
 
59(13.9
) 
 
0.95 
 
14 
(13.1) 
 
16 
(15.0) 
 
0.83 
      FFP transfusion 
26 
(24.3) 
 
45(10.6
) 
 
<0.0
1 
 
26 
(24.3) 
 
12 
(11.2) 
 
<0.0
1 
      Cryoprecipitate 
transfusion 4 (3.7) 
 
26(6.1) 
 
0.48 
 
4 (3.7) 
 
5 (4.7) 
 
1 
            12 Hours bleeding (ml, 
median, IQR) 
450(35
0) 
 
450(32
5) 
 
0.49 
 
450(35
0) 
 
500(36
2) 
 
0.15 
Reoperation  for Bleeding 7 (6.5) 
 
30(7.1) 
 
1 
 
7 (6.5) 
 
8 (7.5) 
 
1 
Renal Failure 
36 
(33.6) 
 
110(25.
9) 
 
0.11 
 
36 
(33.6) 
 
31 
(29.0) 
 
0.45 
CVA  5 (4.7) 
 
11(2.5) 
 
0.44 
 
5 (4.7) 
 
6 (5.6) 
 
1 
Definitions: Major bleeding as defined in the method section. Renal failure as per any RIFLE criteria. RBC: red blood cells, 
PLT: platelets, FFP: fresh frozen plasma, CVA: cerebrovascular accident. IQR: inter-quantile range. Data are expressed as 
number of events and percentages or otherwise expressed.        
Table 4. Adjusted Cox proportional hazard model for patient mortality 
      Multivariate Analysis   
Parameter (reference level) Level                        HR(95% CI) p value 
Aprotinin (no) yes 1.14(0.62-2.08) 0.66 
     Hyperthension(no) yes 2.05(1.13-3.69) 0.01
     COPD(no) 
 
yes 3.36(1.85-6.11) <0.01
     Reduced LVEF(no) yes 2.18(1.23-3.84) <0.01
     Post-operative Bleeding (no)† yes 1.78(0.96-3.28) 0.06
     Post-operative Transfusion(no)‡ yes 2.79(1.8-3.4) 0.01
 
Definitions: COPD: chronic obstructive pulmonary disease, LVEF: left ventricular ejection fraction 
†: Defined as major post-operative event 
‡: Defined as any blood product transfusion 
     
 
 
  
 
 
